RE:RE:RE:Biogen update Not sure if anyone else picked up on what was said in this last article.
It is expected to restrict the number of people who can receive the medication. The coverage policy would also apply to other drugs in this class -- monoclonal antibodies that target amyloid, or plaque, for the treatment of Alzheimer's disease -- that the Food and Drug Administration may approve in the future.